Evaluation of Autonomic System Before and After Anticholinergic Treatment in Women With Overactive Bladder
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The aim of the study is to evaluate changes in autonomic nervous system following treatment with anticholinergic medication for OAB symptoms.
Heart variability as a measure of the functioning of the autonomic nervous system will be recorded before and three months following treatment with solifenacin succinate 10 mg daily.
| Condition | Intervention |
|---|---|
|
Overactive Bladder |
Procedure: ECG recording |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Observational Study on the Effect of Anticholinergic on the Autonomic System in Women With OAB |
- Changes in heart variability following treatment with Solifenacin succinate 10 mg [ Time Frame: 24 months ] [ Designated as safety issue: No ]
- Correlation between changes in clinical symptoms of OAB abd changes in heart rate variability [ Time Frame: 24 months ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 30 |
| Study Start Date: | September 2011 |
| Estimated Study Completion Date: | September 2013 |
| Estimated Primary Completion Date: | September 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Women with OAB
Patients that will be diagnosed as having OAB syndrome by an urogynecologist based on their clinical symptoms (urinary urgency, with or without urinary urgency incontinence, urinary frequency or nocturia).
|
Procedure: ECG recording
At baseline and following 3 months on anticholinergic medications patients, ECG recording will be conducted.
Other Name: Electro cardiogram recording
|
Detailed Description:
30 women with clinical diagnosis of overactive bladder will be recruited for the study. An ECG strip for fifteen minutes at rest will be recorded through a 12-bit analog/digital data acquisition card (National Instruments, Austin TX) with a sampling frequency of 200 Hz and stored in a computer for offline studies. The digitized ECG signals will than processed and analyzed via dedicated robust software to detect the R wave peaks. The R point of each QRS complex was defined and the interval between two consecutive R points (the R-R interval) was computed. All R-R intervals will be visually inspected and manually edited if necessary to exclude background noise and artifacts. The edited segments accounts for less than 1% in each patient. A "clean" 2-5-min segment (preferably unedited) will be used for the analyses. An autoregressive model with the order of 16 was will be used to estimate the power spectrum densities of HRV. The power spectra are quantified by measuring the area under the following frequency bands: low-frequency (LF) (0.04-0.15 Hz) known to represents sympathetic activity, and high-frequency (HF) (0.15-0.4 Hz) which represents parasympathetic activity.
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Patients were diagnosed as having OAB syndrome by an urogynecologist based on their clinical symptoms (urinary urgency, with or without urinary urgency incontinence, urinary frequency or nocturia).
Inclusion Criteria:
Clinical diagnosis of OAB
Exclusion Criteria:
1) stress urinary incontinence and voiding symptoms, 2) pregnancy, 3) pathological conditions that can interfere with the ANS, (e.g. coronary heart disease, heart failure, or other cardiac conditions, hypertension, neurological diseases or diabetes , 4) medications that can interfere with the ANS, including beta-receptor agonists or antagonists, antiarrhythmic agents or antihypertensive drugs, anticholinergic agents or adrenergic alpha-antagonists, tricyclic or serotoninergic antidepressants.
Contacts and Locations| Contact: Dalia Kesner, MD | DALIAKE@clalit.org.il | |
| Contact: Lior Lowenstein, MD | 0502061434 | Lowensteinmd@gmail.com |
| Israel | |
| Zvolon Medical Center | Not yet recruiting |
| Haifa, Israel, 34987 | |
| Contact: Lior Lowenstein, MD 97248542612 LowensteinMD@gmail.com | |
| Principal Investigator: Dalia Kesner, MD | |
| Sub-Investigator: Lior Lowenstein, MD | |
| Sub-Investigator: Eyal Goldshmith, MD | |
| Sub-Investigator: Talma Rosen, RN | |
| Study Chair: | Lior Lowensrtein, MD | Rambam Health Care Campus |
More Information
Publications:
| Responsible Party: | Dalia Kesner, Kupat Hulim Clalit |
| ClinicalTrials.gov Identifier: | NCT01409512 History of Changes |
| Other Study ID Numbers: | 117/2011 |
| Study First Received: | August 3, 2011 |
| Last Updated: | August 3, 2011 |
| Health Authority: | Israel: Ethics Commission |
Keywords provided by Rambam Health Care Campus:
|
Heart rate variability, anti cholinergic medication |
Additional relevant MeSH terms:
|
Urinary Bladder, Overactive Urinary Bladder Diseases Urologic Diseases Urological Manifestations Signs and Symptoms Cholinergic Antagonists |
Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on May 16, 2013